Evidence map›Paper›PMID 34087162›Full record

ArticleCancer cell2021

Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.

Toshiro Hara, Rony Chanoch-Myers, Nathan D Mathewson, Chad Myskiw, Lyla Atta, Lillian Bussema, Stephen W Eichhorn, Alissa C Greenwald, Gabriela S Kinker, Christopher Rodman and 11 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 386 papers.

0numbers the graph read from it
0cells of the map it votes in
386citing papers in PubMed
36.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

386 citing papers in PubMed, 562 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

326 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Toshiro HaraDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Rony Chanoch-MyersDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 761001, Israel.
Nathan D MathewsonBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Cancer Immunology and Virology, Department of Microbiology and Immunobiology, Department of Neurology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
Chad MyskiwLaboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Lyla AttaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Lillian BussemaDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Stephen W EichhornHoward Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA; Department of Chemistry and Chemical Biology, Department of Physics, Harvard University, Cambridge, MA 02138, USA.
Alissa C GreenwaldDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 761001, Israel.
Gabriela S KinkerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 761001, Israel; Department of Physiology, Institute of Bioscience, University of Sao Paulo, Sao Paulo, Brazil.
Christopher RodmanDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
L Nicolas Gonzalez CastroDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Neurology and Center for Neuro-Oncology, Brigham and Women's - Dana-Farber Cancer Center and Harvard Medical School, Boston, MA 02115, USA.
Hiroaki WakimotoDepartment of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Orit Rozenblatt-RosenKlarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Xiaowei ZhuangHoward Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA; Department of Chemistry and Chemical Biology, Department of Physics, Harvard University, Cambridge, MA 02138, USA.
Jean FanDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Tony HunterLaboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Inder M VermaLaboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Kai W WucherpfennigBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Cancer Immunology and Virology, Department of Microbiology and Immunobiology, Department of Neurology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
Aviv RegevKlarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA 02139, USA.
Mario L SuvàDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: suva.mario@mgh.harvard.edu.
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 761001, Israel. Electronic address: itayt@weizmann.ac.il.
Broad Institute · USSalk Institute for Biological Studies · USWeizmann Institute of Science · ILHarvard University · USHoward Hughes Medical Institute · USJohns Hopkins University · USUniversidade de São Paulo · BR

Funding

Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8M
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Benjamin Harris Kann · 2013 to 2026
$33.5M
Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
Dissecting the cellular hierarchies of malignant gliomas by single-cell functional genomicsR37CA245523 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Mario Luca Suva · 2020 to 2026
$2.8M
Molecular Mechanisms and Therapeutic Approaches to Malignant GliomasR01CA195613 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI HUNTER, TONY R. · 2016 to 2019
$2.7M
Howard Hughes Medical InstituteNCI NIH HHS K12 CA090354NCI NIH HHS L30 CA231679NCI NIH HHS P30 CA014195NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA195613NCI NIH HHS R37 CA245523
6 · The paper itself

Abstract

The mesenchymal subtype of glioblastoma is thought to be determined by both cancer cell-intrinsic alterations and extrinsic cellular interactions, but remains poorly understood. Here, we dissect glioblastoma-to-microenvironment interactions by single-cell RNA sequencing analysis of human tumors and model systems, combined with functional experiments. We demonstrate that macrophages induce a transition of glioblastoma cells into mesenchymal-like (MES-like) states. This effect is mediated, both in vitro and in vivo, by macrophage-derived oncostatin M (OSM) that interacts with its receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells and activates STAT3. We show that MES-like glioblastoma states are also associated with increased expression of a mesenchymal program in macrophages and with increased cytotoxicity of T cells, highlighting extensive alterations of the immune microenvironment with potential therapeutic implications.

Indexed as

AnimalsBrain NeoplasmsCells, CulturedCytokine Receptor gp130Cytotoxicity, ImmunologicGene Expression Regulation, NeoplasticGlioblastomaHumansLeukemia Inhibitory Factor Receptor alpha SubunitMiceMice, Inbred C57BLMice, TransgenicOncostatin MOncostatin M Receptor beta SubunitSTAT3 Transcription FactorT-LymphocytesCytokine Receptor gp130IL6ST protein, humanLeukemia Inhibitory Factor Receptor alpha SubunitLIFR protein, humanOncostatin MOncostatin M Receptor beta SubunitOSMR protein, humanSTAT3 protein, humanSTAT3 Transcription FactorGBMglioblastomamacrophagemesenchymalOSMscRNA-seqtumor microenvironment

Identifiers

PMID34087162
PMCPMC8366750
OpenAlexW3165863602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.